2021

Mahindra, A. et al. (2021) Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE, 16(11), e0260283. (doi: 10.1371/journal.pone.0260283) (PMID:34793553) (PMCID:PMC8601423)

Morgan, D. C. et al. (2021) Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalisation. Peptide Science, 113(4), e24217. (doi: 10.1002/pep2.24217) (PMID:33615115) (PMCID:PMC7883042)

2020

Mahindra, A., Janha, O., Mapesa, K., Sanchez Azqueta, A., Alam, M. M. , Amambua-Ngwa, A., Nwakanma, D. C., Tobin, A. B. and Jamieson, A. G. (2020) Development of potent PfCLK3 inhibitors based on TCMDC-135051 as a new class of antimalarials. Journal of Medicinal Chemistry, 63(17), pp. 9300-9315. (doi: 10.1021/acs.jmedchem.0c00451) (PMID:32787140) (PMCID:PMC7497403)

2019

Alam, M. M. et al. (2019) Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Science, 365(6456), eaau1682. (doi: 10.1126/science.aau1682) (PMID:31467193)

Mahindra, A., Millard, C. J., Black, I., Archibald, L. J., Schwabe, J. W.R. and Jamieson, A. G. (2019) Synthesis of HDAC substrate peptidomimetic inhibitors (SPIs) using Fmoc amino acids incorporating zinc-binding groups. Organic Letters, 21(9), pp. 3178-3182. (doi: 10.1021/acs.orglett.9b00885) (PMID:30998366) (PMCID:PMC6503537)

2018

Girt, G. C., Mahindra, A., Al Jabri, Z. J.H., De Ste Croix, M., Oggioni, M. R. and Jamieson, A. G. (2018) Lipopeptidomimetics derived from teixobactin have potent antibacterial activity against Staphylococcus aureus. Chemical Communications, 54(22), pp. 2767-2770. (doi: 10.1039/C7CC06093A) (PMID:29484340)

Articles

Mahindra, A. et al. (2021) Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE, 16(11), e0260283. (doi: 10.1371/journal.pone.0260283) (PMID:34793553) (PMCID:PMC8601423)

Morgan, D. C. et al. (2021) Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalisation. Peptide Science, 113(4), e24217. (doi: 10.1002/pep2.24217) (PMID:33615115) (PMCID:PMC7883042)

Mahindra, A., Janha, O., Mapesa, K., Sanchez Azqueta, A., Alam, M. M. , Amambua-Ngwa, A., Nwakanma, D. C., Tobin, A. B. and Jamieson, A. G. (2020) Development of potent PfCLK3 inhibitors based on TCMDC-135051 as a new class of antimalarials. Journal of Medicinal Chemistry, 63(17), pp. 9300-9315. (doi: 10.1021/acs.jmedchem.0c00451) (PMID:32787140) (PMCID:PMC7497403)

Alam, M. M. et al. (2019) Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Science, 365(6456), eaau1682. (doi: 10.1126/science.aau1682) (PMID:31467193)

Mahindra, A., Millard, C. J., Black, I., Archibald, L. J., Schwabe, J. W.R. and Jamieson, A. G. (2019) Synthesis of HDAC substrate peptidomimetic inhibitors (SPIs) using Fmoc amino acids incorporating zinc-binding groups. Organic Letters, 21(9), pp. 3178-3182. (doi: 10.1021/acs.orglett.9b00885) (PMID:30998366) (PMCID:PMC6503537)

Girt, G. C., Mahindra, A., Al Jabri, Z. J.H., De Ste Croix, M., Oggioni, M. R. and Jamieson, A. G. (2018) Lipopeptidomimetics derived from teixobactin have potent antibacterial activity against Staphylococcus aureus. Chemical Communications, 54(22), pp. 2767-2770. (doi: 10.1039/C7CC06093A) (PMID:29484340)